抗Tenascin C抗体(Anti-Tenascin C, Mouse, Rat-Mono antibody)

掲載日情報:2018/11/26 現在Webページ番号:30535

Tenascin Cに対する抗体(Anti-Tenascin C, Mouse, Rat-Mono )です。
本製品は研究用です。研究用以外には使用できません。

価格

[在庫・価格 :2025年11月03日 13時35分現在]

※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
詳細 商品名
  • 商品コード
  • メーカー
  • 包装
  • 価格
  • 在庫
  • 法規制等
納期 文献数
Anti-Tenascin C, Mouse, Rat-Mono(578)
10日程度 ※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。 14
  • 使用文献
  • メーカーサイト
  • お問い合わせ
説明文
別名:150-225
クローン:578
Genbank No: 3371
別包装品 別包装品あり
法規制等
保存条件 -20℃ 法規備考
抗原種 Human/Mouse 免疫動物 Rat クラス IgG 標識 Unlabeled
交差性 Human 適用 IC,Neutralising,Western Blot
クロナリティ Monoclonal フォーマット 性状 Protein A/G Affinity Purified 吸収処理
掲載カタログ

製品記事
関連記事
Anti-Human/Mouse Tenascin C MAb (Clone 578)
2~3週間 ※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。 11
  • 使用文献
  • メーカーサイト
  • お問い合わせ
説明文
※受注発注品。形状:溶液または凍結乾燥
別名:150-225
クローン:578
Genbank No: 3371
別包装品 別包装品あり
法規制等
保存条件 -20℃ 法規備考
抗原種 免疫動物 Rat クラス IgG 標識 Unlabeled
交差性 Human 適用 IC,Neutralising,Western Blot
クロナリティ Monoclonal フォーマット 性状 Protein A/G Affinity Purified 吸収処理
掲載カタログ

製品記事 使いっきり抗体
関連記事

[在庫・価格 :2025年11月03日 13時35分現在]

※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。

Anti-Tenascin C, Mouse, Rat-Mono(578)

文献数: 14

説明文 別名:150-225
クローン:578
Genbank No: 3371
別包装品 別包装品あり
法規制等
保存条件 -20℃ 法規備考
抗原種 Human/Mouse 免疫動物 Rat
交差性 Human 適用 IC,Neutralising,Western Blot
標識 Unlabeled 性状 Protein A/G Affinity Purified
吸収処理 クラス IgG
クロナリティ Monoclonal フォーマット
掲載カタログ

製品記事
関連記事

Anti-Human/Mouse Tenascin C MAb (Clone 578)

文献数: 11

説明文 ※受注発注品。形状:溶液または凍結乾燥
別名:150-225
クローン:578
Genbank No: 3371
別包装品 別包装品あり
法規制等
保存条件 -20℃ 法規備考
抗原種 免疫動物 Rat
交差性 Human 適用 IC,Neutralising,Western Blot
標識 Unlabeled 性状 Protein A/G Affinity Purified
吸収処理 クラス IgG
クロナリティ Monoclonal フォーマット
掲載カタログ

製品記事 使いっきり抗体
関連記事



目次に戻る

Product Details

Species ReactivityHuman, Mouse
LabelUnconjugated
ImmunogenMouse immature astrocyte-derived Tenascin C
SourceMonoclonal Rat IgG2A Clone # 578
PurificationProtein A or G purified from hybridoma culture supernatant
SpecificityDetect human and mouse Tenascin C in Western blots.


目次に戻る

Applications and Data

 Recommended
Concentration
Sample
Western BlotMorganti, M. et al. (1990) Exp. Neurol. 109:98.
Immunocytochemistry8-25 µg/mLSee below
NeutralizationHusmann, K. et al. (1992) J. Cell Biol. 116:1475.


Immunocytochemistry
Tenascin C in U‑118 MG Human Cell Line.
Tenascin C was detected in immersion fixed U‑118 MG human glioblastoma/astrocytoma cell line using Rat Anti-Human/Mouse Tenascin C Monoclonal Antibody (Catalog # MAB2138) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Rat IgG Secondary Antibody (yellow; Catalog # NL013) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Cells on Coverslips.


目次に戻る

Related Product & Information

Entrez Gene IDs3371 (Human); 21923 (Mouse); 116640 (Rat)
BackgroundTenascin C
background_contentBackground:
Tenascin C
Tenascin C, also known as hexabrachion, cytotactin, neuronectin, GMEM, JI, myotendinous antigen, glioma-associated-extracellular matrix antigen, and GP 150‑225, is a member of the Tenascin family of extracellular matrix proteins. It is secreted as a disulfide-linked homohexamer whose subunits can vary in size from approximately 200 kDa to over 300 kDa due to differences in glycosylation (1). Rotary-shadowed electron micrographs of the purified molecule show six strands joined to one another at one end in a globular domain with each arm terminating in a knob-like structure (2, 3). The human Tenascin C monomer is synthesized as a precursor with a 22 amino acid (aa) signal sequence and a 2179 aa mature chain. The mature chain consists of a coiled-coil region (aa 118‑145), followed by15 EGF‑like domains, 15 fibronectin type-III domains, and a fibrinogen C-terminal domain. In addition, there are 23 potential sites of N‑linked glycosylation. Alternative splicing within the fibronectin type-III repeats produces six isoforms for human Tenascin C. Mature human Tenascin C (isoform 1) shares 84% aa sequence identity with mature mouse Tenascin C. In the developing embryo, Tenascin C is expressed during neural, skeletal, and vascular morphogenesis (1, 2). In the adult, it virtually disappears with continued basal expression detectable only in tendon-associated tissues (1, 2). However, great up-regulation in expression occurs in tissues undergoing remodeling processes seen during wound repair and neovascularization or in pathological states such as inflammation or tumorigenesis (1, 4, 5). Biologically, Tenascin C functions as an adhesion-modulatory extracellular matrix protein (1, 4‑8). Specifically, it antagonizes the adhesive effects of fibronectin, and impacts the ability of fibroblasts to deposit and contract the matrix by affecting the morphology and signaling pathways of adherent cells (5‑7). Tenascin C acts by blocking syndecan-4 binding at the edges of the wound and by suppressing fibronectin-mediated activation of RhoA and focal adhesion kinase (FAK) (4‑8). Tenascin C thus promotes epidermal cell migration and proliferation during wound repair.


目次に戻る

Citations

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
  1. Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation.
    Authors: Procopio M, Laszlo C, Al Labban D, Kim D, Bordignon P, Jo S, Goruppi S, Menietti E, Ostano P, Ala U, Provero P, Hoetzenecker W, Neel V, Kilarski W, Swartz M, Brisken C, Lefort K, Dotto G
    Nat Cell Biol, 2015;17(9):1193-204.
    Species: Mouse
    Sample Type: Whole Tissue
    Application: IHC - Not specified

  2. Temporal expression of growth factors triggered by epiregulin regulates inflammation development.
    Authors: Harada M, Kamimura D, Arima Y, Kohsaka H, Nakatsuji Y, Nishida M, Atsumi T, Meng J, Bando H, Singh R, Sabharwal L, Jiang J, Kumai N, Miyasaka N, Sakoda S, Yamauchi-Takihara K, Ogura H, Hirano T, Murakami M
    J Immunol, 2015;194(3):1039-46.
    Species: Mouse
    Sample Type: In Vivo
    Application: In vivo

  3. The missense mutation p.R1303Q in type XVII collagen underlies junctional epidermolysis bullosa resembling Kindler syndrome.
    Authors: Has, Cristina, Kiritsi, Dimitra, Mellerio, Jemima E, Franzke, Claus-We, Wedgeworth, Emma, Tantcheva-Poor, Iliana, Kernland-Lang, Kristin, Itin, Peter, Simpson, Michael, Dopping-Hepenstal, Patricia, Fujimoto, Wataru, McGrath, John A, Bruckner-Tuderman, Leena
    J Invest Dermatol, 2014;134(3):845-9.
    Species: Human
    Sample Type: Whole Tissue
    Application: IHC - Not specified

  4. Melanoma cell invasiveness is promoted at least in part by the epidermal growth factor-like repeats of tenascin-C.
    Authors: Grahovac, Jelena, Becker, Dorothea, Wells, Alan
    J Invest Dermatol, 2013;133(1):210-20.
    Species: Human
    Sample Type: Cell Lysates
    Application: WB

  5. Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity.
    Authors: Kern JS, Loeckermann S, Fritsch A, Hausser I, Roth W, Magin TM, Mack C, Muller ML, Paul O, Ruther P, Bruckner-Tuderman L
    Mol. Ther., 2009;17(9):1605-15.
    Species: Mouse
    Sample Type: Whole Tissue
    Application: IHC

  6. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy.
    Authors: Fritsch A, Loeckermann S, Kern JS, Braun A, Bosl MR, Bley TA, Schumann H, von Elverfeldt D, Paul D, Erlacher M, Berens von Rautenfeld D, Hausser I, Fassler R, Bruckner-Tuderman L
    J. Clin. Invest., 2008;118(5):1669-79.
    Species: Mouse
    Sample Type: Whole Tissue
    Application: IHC Frozen

  7. ELR-negative CXC chemokine CXCL11 (IP-9/I-TAC) facilitates dermal and epidermal maturation during wound repair.
    Authors: Yates CC, Whaley D, Y-Chen A, Kulesekaran P, Hebda PA, Wells A
    Am. J. Pathol., 2008;173(3):643-52.
    Species: Mouse
    Sample Type: Whole Tissue
    Application: IHC Paraffin-embedded

  8. Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling.
    Authors: Bujak M, Ren G, Kweon HJ, Dobaczewski M, Reddy A, Taffet G, Wang XF, Frangogiannis NG
    Circulation, 2007;116(19):2127-38.
    Species: Mouse
    Sample Type: Whole Tissue
    Application: IHC Paraffin-embedded



目次に戻る

お問い合わせ先

(テクニカルサポート 試薬担当)

reagent@funakoshi.co.jp

製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。